Image: The EKF Quo-Lab HbA1c Analyzer (Photo courtesy of EKF Diagnostics).
A leader in in-vitro diagnostics will exhibit in an upcoming medical congress two point-of-care (POC) analyzers for the rapid assessment of diabetes and related conditions.
The Quo-Lab HbA1c analyzer and the STAT-Site M β-HB by EKF Diagnostics (EKF; Cardiff, UK) will be demonstrated at the Welsh stand during the ArabHealth healthcare exhibition and medical congress, which will take place January 27–30, 2014, at the International Convention and Exhibition Center in Dubai (UAE).
HbA1c monitoring is increasingly used in the detection and management of diabetes: Quo-Lab provides highly accurate, affordable, and easy-to-use technology, which uses only 4 µL of venous or finger prick blood to deliver results within four minutes. The analyzer, which was launched mid-2013, has had a good reception, with nearly 1,300 being sold globally to date. The Quo-Lab analyzer is designed to meet the needs of GP surgeries, clinics, and laboratories in emerging economies, where diabetes has become a growing public health issue.
The second analyzer to be demonstrated, the STAT-Site M β-HB, is a quantitative strip-based test for ß-Hydroxybutyrate (ß-HB). The device provides quick and easy assessment of diabetic ketoacidosis (DKA), delivers results in less than 80 seconds, and it is CE marked.
Using the STAT-Site M ß-HB, the presence and degree of ketosis can be assessed at POC by accurately measuring blood levels of ß-HB, which accounts for 78% of the three ketone bodies, from just 10 µL of serum or plasma. This provides useful information to deliver quality care when monitoring DKA in newly diagnosed patients, while also reducing time and costs in an emergency room setting.